VYNE Therapeutics Inc.
BRIDGEWATER, NJ · Founded 2011 · CIK 0001566044 · Biotech · Acquired
Topical dermatology therapeutics and transdermal drug delivery formulations
vynetherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $139M
- 4 Form D · Nov 2023
- 35 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 35
- 3 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $50,500,001 | |
| Private capital raised | Form D · SEC | $300,000 | |
| Private capital raised | Form D · SEC | $88,151,508 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2797 | RGENE, INC. | — | — |
| 2798 | Immunocore Holdings plc | — | $140M |
| 2799 | Black Diamond Therapeutics | — | $140M |
| 2800 | VYNE Therapeutics Inc. | — | $139M |
| 2801 | Silverback Therapeutics | — | $139M |
| 2802 | VANQUA BIO, INC. | — | $136M |
| 2803 | Chroma Medicine | — | $135M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- SHARON BARBARIDirector
- Steven BastaDirector · Executive Officer
- STEVEN BASTADirector
- ANTHONY BRUNODirector
- Albert ChaDirector
- David CollierDirector
- John CreecyDirector
- DAVID DOMZALSKIDirector · Executive Officer
- Ted EbelDirector
- MUTYA HARSCHExecutive Officer
- James LarrickDirector · Executive Officer
- PATRICK LEPOREDirector
- Ketan PatelDirector
- Andrew PerlmanDirector
- Aaron RoystonDirector
- ELISABETH SANDOVALDirector
- Edward SchnipperDirector
- IAIN STUARTExecutive Officer
- Scott WhitcupDirector
- TYLER ZERONDAExecutive Officer
Patents
- Uses Of Pan Bet Inhibitorsapplication
- Tofacitinib-containing Anhydrous Elastomer-based Gel Formulationsapplication
- Tofacitinib-containing Anhydrous Elastomer-based Gel Formulationsapplication
- Topical Composition Comprising Tofacitinib And Fingolimodapplication
- Compositions And Methods For Treating Rosacea And Acnegranted
- Wax Foamable Vehicle And Pharmaceutical Compositions Thereofgranted
- Use Of NEUROKININ-1 Antagonists To Treat Pruritusapplication
- Use Of NK-1 Receptor Antagonist Serlopitant In Pruritusgranted
- Compositions, Gels And Foams With Rheology Modulators And Uses Thereofapplication
- Surfactant-free, Water-free Foamable Composition And Breakable Foams And Their Usesapplication
- Compositions, Gels And Foams With Rheology Modulators And Uses Thereofapplication
- Surfactant-free Water-free Foamable Compositions, Breakable Foams And Gels And Their Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.